Male Gonadal Function After Pediatric Hematopoietic Stem Cell Transplantation: A Systematic Review

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Male Gonadal Function After Pediatric Hematopoietic Stem Cell Transplantation : A Systematic Review. / Mathiesen, Sidsel; Andrés-Jensen, Liv; Nielsen, Malene Mejdahl; Sørensen, Kaspar; Ifversen, Marianne; Jahnukainen, Kirsi; Juul, Anders; Müller, Klaus.

I: Transplantation and Cellular Therapy, Bind 28, Nr. 8, 2022, s. 503.e1-503.e15.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Mathiesen, S, Andrés-Jensen, L, Nielsen, MM, Sørensen, K, Ifversen, M, Jahnukainen, K, Juul, A & Müller, K 2022, 'Male Gonadal Function After Pediatric Hematopoietic Stem Cell Transplantation: A Systematic Review', Transplantation and Cellular Therapy, bind 28, nr. 8, s. 503.e1-503.e15. https://doi.org/10.1016/j.jtct.2022.05.036

APA

Mathiesen, S., Andrés-Jensen, L., Nielsen, M. M., Sørensen, K., Ifversen, M., Jahnukainen, K., Juul, A., & Müller, K. (2022). Male Gonadal Function After Pediatric Hematopoietic Stem Cell Transplantation: A Systematic Review. Transplantation and Cellular Therapy, 28(8), 503.e1-503.e15. https://doi.org/10.1016/j.jtct.2022.05.036

Vancouver

Mathiesen S, Andrés-Jensen L, Nielsen MM, Sørensen K, Ifversen M, Jahnukainen K o.a. Male Gonadal Function After Pediatric Hematopoietic Stem Cell Transplantation: A Systematic Review. Transplantation and Cellular Therapy. 2022;28(8):503.e1-503.e15. https://doi.org/10.1016/j.jtct.2022.05.036

Author

Mathiesen, Sidsel ; Andrés-Jensen, Liv ; Nielsen, Malene Mejdahl ; Sørensen, Kaspar ; Ifversen, Marianne ; Jahnukainen, Kirsi ; Juul, Anders ; Müller, Klaus. / Male Gonadal Function After Pediatric Hematopoietic Stem Cell Transplantation : A Systematic Review. I: Transplantation and Cellular Therapy. 2022 ; Bind 28, Nr. 8. s. 503.e1-503.e15.

Bibtex

@article{b7f720eb8c0245b3966ee8a81e31460f,
title = "Male Gonadal Function After Pediatric Hematopoietic Stem Cell Transplantation: A Systematic Review",
abstract = "Male gonadal dysfunction is a frequent late effect after pediatric hematopoietic stem cell transplantation (HSCT) that can lead to disturbances in pubertal development, sexual dysfunction, and infertility. However, no systematic review exists regarding prevalence and risk factors in relation to different treatment regimens. We aimed to systematically evaluate the current evidence regarding the prevalence of male gonadal dysfunction after pediatric HSCT, related risk factors, and the diagnostic value of surrogate markers of spermatogenesis in this patient group. We searched PubMed and Embase using a combination of text words and subject terms. The eligibility screening was conducted using predefined criteria. Data were extracted corresponding to the Leydig cell compartment involved in testosterone production and the germ cell compartment involved in spermatogenesis, respectively. Subsequently, data synthesis was performed. Of 2369 identified records, 25 studies were eligible. The studies were heterogeneous in terms of included diagnoses, gonadotoxic therapy, follow-up time, and definitions of gonadal dysfunction. The data synthesis revealed a preserved Leydig cell function in patients treated with non-total body irradiation (TBI) regimens, whereas the evidence regarding the impact of TBI conditioning on Leydig cell function was conflicting. Based on surrogate markers of spermatogenesis and only limited data on semen quality, the germ cell compartment was affected in half of the patients treated with non-TBI regimens and in nearly all patients treated with TBI conditioning. Testicular irradiation as part of front-line therapy before referral to HSCT led to complete Leydig cell failure and germ cell failure. Evidence regarding the impact of diagnosis, pubertal stage at HSCT, and chronic graft-versus-host disease is limited, as is the evidence of the diagnostic value of surrogate markers of spermatogenesis. Testicular irradiation as part of front-line therapy and TBI conditioning are the main risk factors associated with male gonadal dysfunction after pediatric HSCT; however, impaired spermatogenesis is also observed in half of the patients treated with non-TBI regimens. Methodological shortcomings limit existing evidence, and future studies should include semen quality analyses, follow-up into late adulthood, and evaluation of the cumulative exposure to gonadotoxic therapy.",
keywords = "Gonadal function, Hematopoietic stem cell transplantation, Late effects, Pediatrics",
author = "Sidsel Mathiesen and Liv Andr{\'e}s-Jensen and Nielsen, {Malene Mejdahl} and Kaspar S{\o}rensen and Marianne Ifversen and Kirsi Jahnukainen and Anders Juul and Klaus M{\"u}ller",
note = "Publisher Copyright: {\textcopyright} 2022 The American Society for Transplantation and Cellular Therapy",
year = "2022",
doi = "10.1016/j.jtct.2022.05.036",
language = "English",
volume = "28",
pages = "503.e1--503.e15",
journal = "Transplantation and Cellular Therapy",
issn = "2666-6375",
publisher = "Elsevier",
number = "8",

}

RIS

TY - JOUR

T1 - Male Gonadal Function After Pediatric Hematopoietic Stem Cell Transplantation

T2 - A Systematic Review

AU - Mathiesen, Sidsel

AU - Andrés-Jensen, Liv

AU - Nielsen, Malene Mejdahl

AU - Sørensen, Kaspar

AU - Ifversen, Marianne

AU - Jahnukainen, Kirsi

AU - Juul, Anders

AU - Müller, Klaus

N1 - Publisher Copyright: © 2022 The American Society for Transplantation and Cellular Therapy

PY - 2022

Y1 - 2022

N2 - Male gonadal dysfunction is a frequent late effect after pediatric hematopoietic stem cell transplantation (HSCT) that can lead to disturbances in pubertal development, sexual dysfunction, and infertility. However, no systematic review exists regarding prevalence and risk factors in relation to different treatment regimens. We aimed to systematically evaluate the current evidence regarding the prevalence of male gonadal dysfunction after pediatric HSCT, related risk factors, and the diagnostic value of surrogate markers of spermatogenesis in this patient group. We searched PubMed and Embase using a combination of text words and subject terms. The eligibility screening was conducted using predefined criteria. Data were extracted corresponding to the Leydig cell compartment involved in testosterone production and the germ cell compartment involved in spermatogenesis, respectively. Subsequently, data synthesis was performed. Of 2369 identified records, 25 studies were eligible. The studies were heterogeneous in terms of included diagnoses, gonadotoxic therapy, follow-up time, and definitions of gonadal dysfunction. The data synthesis revealed a preserved Leydig cell function in patients treated with non-total body irradiation (TBI) regimens, whereas the evidence regarding the impact of TBI conditioning on Leydig cell function was conflicting. Based on surrogate markers of spermatogenesis and only limited data on semen quality, the germ cell compartment was affected in half of the patients treated with non-TBI regimens and in nearly all patients treated with TBI conditioning. Testicular irradiation as part of front-line therapy before referral to HSCT led to complete Leydig cell failure and germ cell failure. Evidence regarding the impact of diagnosis, pubertal stage at HSCT, and chronic graft-versus-host disease is limited, as is the evidence of the diagnostic value of surrogate markers of spermatogenesis. Testicular irradiation as part of front-line therapy and TBI conditioning are the main risk factors associated with male gonadal dysfunction after pediatric HSCT; however, impaired spermatogenesis is also observed in half of the patients treated with non-TBI regimens. Methodological shortcomings limit existing evidence, and future studies should include semen quality analyses, follow-up into late adulthood, and evaluation of the cumulative exposure to gonadotoxic therapy.

AB - Male gonadal dysfunction is a frequent late effect after pediatric hematopoietic stem cell transplantation (HSCT) that can lead to disturbances in pubertal development, sexual dysfunction, and infertility. However, no systematic review exists regarding prevalence and risk factors in relation to different treatment regimens. We aimed to systematically evaluate the current evidence regarding the prevalence of male gonadal dysfunction after pediatric HSCT, related risk factors, and the diagnostic value of surrogate markers of spermatogenesis in this patient group. We searched PubMed and Embase using a combination of text words and subject terms. The eligibility screening was conducted using predefined criteria. Data were extracted corresponding to the Leydig cell compartment involved in testosterone production and the germ cell compartment involved in spermatogenesis, respectively. Subsequently, data synthesis was performed. Of 2369 identified records, 25 studies were eligible. The studies were heterogeneous in terms of included diagnoses, gonadotoxic therapy, follow-up time, and definitions of gonadal dysfunction. The data synthesis revealed a preserved Leydig cell function in patients treated with non-total body irradiation (TBI) regimens, whereas the evidence regarding the impact of TBI conditioning on Leydig cell function was conflicting. Based on surrogate markers of spermatogenesis and only limited data on semen quality, the germ cell compartment was affected in half of the patients treated with non-TBI regimens and in nearly all patients treated with TBI conditioning. Testicular irradiation as part of front-line therapy before referral to HSCT led to complete Leydig cell failure and germ cell failure. Evidence regarding the impact of diagnosis, pubertal stage at HSCT, and chronic graft-versus-host disease is limited, as is the evidence of the diagnostic value of surrogate markers of spermatogenesis. Testicular irradiation as part of front-line therapy and TBI conditioning are the main risk factors associated with male gonadal dysfunction after pediatric HSCT; however, impaired spermatogenesis is also observed in half of the patients treated with non-TBI regimens. Methodological shortcomings limit existing evidence, and future studies should include semen quality analyses, follow-up into late adulthood, and evaluation of the cumulative exposure to gonadotoxic therapy.

KW - Gonadal function

KW - Hematopoietic stem cell transplantation

KW - Late effects

KW - Pediatrics

U2 - 10.1016/j.jtct.2022.05.036

DO - 10.1016/j.jtct.2022.05.036

M3 - Journal article

C2 - 35644480

AN - SCOPUS:85133303902

VL - 28

SP - 503.e1-503.e15

JO - Transplantation and Cellular Therapy

JF - Transplantation and Cellular Therapy

SN - 2666-6375

IS - 8

ER -

ID: 341060715